BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announces its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami. CEO Jason Matuszewski will engage in a fireside chat and one-on-one meetings.
BioStem Technologies leverages its proprietary BioREtain® processing method to develop and manufacture allografts. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products. Their facility in Pompano Beach, Florida, is FDA registered and AATB accredited, operating under cGTP and cGMP standards.
BioStem Technologies (OTC: BSEM), un'azienda MedTech specializzata in prodotti derivati dalla placenta per la cura avanzata delle ferite, annuncia la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità di Goldman Sachs a Miami. Il CEO Jason Matuszewski parteciperà a una conversazione informale e a incontri individuali.
BioStem Technologies utilizza il suo esclusivo metodo di lavorazione BioREtain® per sviluppare e produrre allograft. Il portafoglio prodotti dell'azienda comprende AmnioWrap2™, VENDAJE®, VENDAJE AC® e VENDAJE OPTIC®. La loro struttura a Pompano Beach, Florida, è registrata presso la FDA e accreditata AATB, operando secondo gli standard cGTP e cGMP.
BioStem Technologies (OTC: BSEM), una empresa MedTech especializada en productos derivados de la placenta para el cuidado avanzado de heridas, anuncia su participación en la 46ª Conferencia Global Anual de Salud de Goldman Sachs en Miami. El CEO Jason Matuszewski participará en una charla informal y en reuniones individuales.
BioStem Technologies utiliza su método exclusivo de procesamiento BioREtain® para desarrollar y fabricar aloinjertos. El portafolio de la compañía incluye los productos AmnioWrap2™, VENDAJE®, VENDAJE AC® y VENDAJE OPTIC®. Su instalación en Pompano Beach, Florida, está registrada en la FDA y acreditada por la AATB, operando bajo los estándares cGTP y cGMP.
BioStem Technologies (OTC: BSEM)는 첨단 상처 치료를 위한 태반 유래 제품을 전문으로 하는 MedTech 기업으로, 마이애미에서 열리는 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO 제이슨 마투셰프스키가 파이어사이드 채팅과 일대일 미팅에 참여할 예정입니다.
BioStem Technologies는 독자적인 BioREtain® 가공 방식을 활용하여 동종 이식편을 개발 및 제조합니다. 회사의 제품군에는 AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®이 포함되어 있습니다. 플로리다 팜파노 비치에 위치한 시설은 FDA 등록 및 AATB 인증을 받았으며, cGTP 및 cGMP 기준에 따라 운영되고 있습니다.
BioStem Technologies (OTC : BSEM), une entreprise MedTech spécialisée dans les produits dérivés du placenta pour les soins avancés des plaies, annonce sa participation à la 46e conférence mondiale annuelle sur la santé de Goldman Sachs à Miami. Le PDG Jason Matuszewski participera à une discussion informelle et à des réunions en tête-à-tête.
BioStem Technologies utilise sa méthode exclusive de traitement BioREtain® pour développer et fabriquer des allogreffes. Le portefeuille de produits de l'entreprise comprend AmnioWrap2™, VENDAJE®, VENDAJE AC® et VENDAJE OPTIC®. Leur installation à Pompano Beach, en Floride, est enregistrée auprès de la FDA et accréditée par l'AATB, fonctionnant selon les normes cGTP et cGMP.
BioStem Technologies (OTC: BSEM), ein MedTech-Unternehmen, das sich auf plazentabasierten Produkte für die fortschrittliche Wundversorgung spezialisiert hat, kündigt seine Teilnahme an der 46. jährlichen globalen Gesundheitskonferenz von Goldman Sachs in Miami an. CEO Jason Matuszewski wird an einem Fireside-Chat sowie Einzelgesprächen teilnehmen.
BioStem Technologies nutzt seine proprietäre BioREtain®-Verarbeitungstechnologie zur Entwicklung und Herstellung von Allografts. Zum Produktportfolio des Unternehmens gehören AmnioWrap2™, VENDAJE®, VENDAJE AC® und VENDAJE OPTIC®. Die Anlage in Pompano Beach, Florida, ist bei der FDA registriert und AATB-akkreditiert und arbeitet nach cGTP- und cGMP-Standards.
- None.
- None.
POMPANO BEACH, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami.
Jason Matuszewski, the Company’s CEO, will participate in a fireside chat and will be available for one-on-one meetings. For conference attendees wishing to schedule a meeting, please contact Noah Agron, VP Corporate Finance and Strategy, at nagron@biostemtech.com.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on X and LinkedIn.
Contact BioStem Technologies, Inc.:
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Investor Relations:
Adam Holdsworth
E-Mail: adam@biostemtech.com
Phone: 917-497-9287
FAQ
What is BioStem Technologies (BSEM) presenting at the Goldman Sachs Healthcare Conference 2025?
What products does BioStem Technologies (BSEM) manufacture?
Is BioStem Technologies (BSEM) FDA registered?
What is BioStem Technologies' (BSEM) main business focus?
